• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    REGENXBIO Inc. - Common Stock (NQ:RGNX)

    8.030 +0.040 (+0.50%)
    Streaming Delayed Price Updated: 2:33 PM EST, Feb 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 489,542
    Open 7.930
    Bid (Size) 8.020 (100)
    Ask (Size) 8.040 (100)
    Prev. Close 7.990
    Today's Range 7.735 - 8.060
    52wk Range 5.035 - 16.19
    Shares Outstanding 43,466,186
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
    From The Rosen Law Firm PA
    Via GlobeNewswire

    Performance

    YTD
    -40.8%
    -40.8%
    1 Month
    -43.0%
    -43.0%
    3 Month
    -27.9%
    -27.9%
    6 Month
    -7.8%
    -7.8%
    1 Year
    +5.9%
    +5.9%

    More News

    Read More
    News headline image
    REGENXBIO Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – RGNX
    From DJS Law Group
    Via Business Wire
    News headline image
    RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the REGENXBIO, Inc. Securities Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    News headline image
    Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
    Via MarketMinute
    News headline image
    Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street ↗
    Via Stocktwits
    News headline image
    Why Did RGNX Shares Plummet 19% After-Hours Today? ↗
    Via Stocktwits
    Monday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
    Via NewMediaWire
    News headline image
    Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
    Via TheNewswire.com
    Gapping stocks in Wednesday's session ↗
    Via Chartmill
    News headline image
    RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗
    Via Stocktwits
    Top movers in Wednesday's pre-market session ↗
    Via Chartmill
    News headline image
    My Top 4 Stocks to Buy in Early 2026 ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy
    News headline image
    Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
    Via MarketMinute
    News headline image
    REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress ↗
    Via Chartmill
    News headline image
    The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts ↗
    Via Benzinga

    Frequently Asked Questions

    Is REGENXBIO Inc. - Common Stock publicly traded?
    Yes, REGENXBIO Inc. - Common Stock is publicly traded.
    What exchange does REGENXBIO Inc. - Common Stock trade on?
    REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for REGENXBIO Inc. - Common Stock?
    The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
    What is the current price of REGENXBIO Inc. - Common Stock?
    The current price of REGENXBIO Inc. - Common Stock is 8.030
    When was REGENXBIO Inc. - Common Stock last traded?
    The last trade of REGENXBIO Inc. - Common Stock was at 02/17/26 02:33 PM ET
    What is the market capitalization of REGENXBIO Inc. - Common Stock?
    The market capitalization of REGENXBIO Inc. - Common Stock is 349.03M
    How many shares of REGENXBIO Inc. - Common Stock are outstanding?
    REGENXBIO Inc. - Common Stock has 349M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.